Results from sub-study 03A of KEYMAKER-U03, an international, open-label, rolling-arm, phase I/II umbrella trial, spotlight the promise of pembrolizumab-based regimens combined with tyrosine kinase ...
Efficacy and safety of XELOX combined with anlotinib and penpulimab vs XELOX as adjuvant therapy in ctDNA-positive gastric and esophagogastric junction adenocarcinoma: A protocol for a randomized, ...
Keymaker Youth Support Services Inc. is committed to providing individualized training to youth and young adults and their support network members to increase focus, connection, and performance. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results